New immune cells for B-cell lymphoma that has returned
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of immune cell therapy (called AbTCR T-cells) that targets two markers (CD19 and CD22) found on your lymphoma cells. The goal is to see if these modified cells can safely and effectively destroy your cancer when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lymphoma must have the CD19 and CD22 markers on the cancer cells.
- You must have tried at least two prior treatments and your lymphoma has not responded or has come back.
- Your heart, liver, kidneys, lungs, and bone marrow must be working well enough.
- You must not have had a stem cell transplant using donor cells, and you must not have serious infections like hepatitis B or C, HIV, or syphilis.
- You must agree to use effective birth control for 1 year after the cell infusion if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new CAR-T cell therapy designed to target and destroy cancer cells that have the CD19 marker. It may help people with large B-cell lymphoma that has relapsed or not responded to standard treatments.
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hear when a new Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.